On April 6, 2022 (the Effective Date"), Prelude Therapeutics Incorporated and Deborah Morosini, the Company's EVP and Chief of Clinical Affairs, agreed that, effective as of the Effective Date, Dr. Morosini shall resign from her role as an officer of the Company and will transition into a role of Strategic Advisor to the President from the Effective Date until May 5, 2022, upon which Dr. Morosini's employment with the Company shall terminate (the Separation Date").
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.09 USD | -0.73% | +5.96% | -4.22% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.22% | 225M | |
+44.48% | 55.07B | |
-0.86% | 41.79B | |
+43.68% | 40.22B | |
-7.59% | 28.17B | |
+12.30% | 26.28B | |
-21.83% | 18.93B | |
+7.15% | 13.03B | |
+29.40% | 12.26B | |
+25.15% | 12.21B |
- Stock Market
- Equities
- PRLD Stock
- News Prelude Therapeutics Incorporated
- Deborah Morosini Resigns as an Officer of Prelude Therapeutics Incorporated and Will Transition into a Role of Strategic Advisor to the President